WHO preferred product characteristics for new vaccines against tuberculosis
WHO preferred product characteristics for new vaccines against tuberculosis
About this item
Full title
Author / Creator
Publisher
United States: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
United States: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
For extensively drug-resistant tuberculosis, the costs associated with treatment are exorbitant and even the best attempts at curing the disease might prove insufficient.1 The accelerated development of new vaccines against tuberculosis suitable for licensing, informing policy decision making and optimal use, leading to a public health effect where...
Alternative Titles
Full title
WHO preferred product characteristics for new vaccines against tuberculosis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2081544821
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2081544821
Other Identifiers
ISSN
1473-3099
E-ISSN
1474-4457
DOI
10.1016/S1473-3099(18)30421-3
